Grifols is advancing plans to list a minority stake in its U.S. Biopharma business through an initial public offering, subject to market and regulatory conditions. The transaction aims to raise capital to support debt reduction and fund growth initiatives, while allowing the parent company to retain control and continue its listing in Spain. Post-IPO, the U.S. Biopharma unit will operate with an independent board, dedicated leadership, and a distinct governance framework, enabling a more focused strategy aligned with investor demand for a simplified, U.S.-centric plasma business.
The U.S. Biopharma business represents a significant asset, operating in a market that supplies over 60% of global plasma and is expected to grow steadily. Grifols’ vertically integrated model spans plasma collection, manufacturing, and distribution, ensuring supply continuity and cost efficiency. The IPO also complements broader self-sufficiency initiatives in markets such as Egypt and Canada, where the company is expanding plasma capacity and improving supply security through partnerships and infrastructure investments. This dual strategy, leveraging a mature U.S. platform while scaling international operations, positions the company to enhance margins, diversify revenue streams, and support long-term financial stability.
